SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.00837 | 0.00794 | 0.00882 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0154 | 0.0148 | 0.016 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00704 | -0.00778 | -0.0063 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.543 | 0.509 | 0.58 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.539 | 0.505 | 0.576 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer death from any cause on SGLT-2i (Incl. Empa) (Matched to DPP-4i) than on DPP-4i (Matched to SGLT-2i) | 142 | 128 | 159 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | SGLT-2i (Incl. Empa) (Matched to DPP-4i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of any sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including (incl.) new users of empagliflozin (empa). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of any SGLT-2i between November 2012 and December 2019. New user of any SGLT-2i were matched to new users of DPP-4i using a 1:1 propensity score (PS)-matching approach. | 1,371 | 163,812 | EG000 | ClinicalTrials.gov |
| Group 2 | DPP-4i (Matched to SGLT-2i) | Patients with type 2 diabetes mellitus (T2DM), who were new users of dipeptidyl peptidase-4 inhibitors (DPP-4i). The study used secondary data sources from 11 countries (Denmark, Finland, Germany, Israel, Japan, Norway, South Korea, Spain, Sweden, Taiwan and the United Kingdom (UK CPRD, UK THIN) to identify new users of DPP-4i between November 2012 and December 2019. New users of DPP-4i where matched to new users of any SGLT-2i using a 1:1 propensity score (PS)-matching approach. | 2,524 | 163,812 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes | ClinicalTrials.gov |
| NCT number | NCT03817463 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Diabetes Mellitus, Type 2 | ClinicalTrials.gov |
| Interventions | Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor | ClinicalTrials.gov |
| Lead sponsor | Boehringer Ingelheim | ClinicalTrials.gov |
| Results first posted | 2024-09-23 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03817463?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.